Improving CSF biomarkers' performance for predicting progression from mild cognitive impairment to Alzheimer's disease by considering different confounding factors: A meta-analysis

Frontiers in Aging Neuroscience

Volumn 6, Issue OCT, 2014, Pages

  Ferreira, Daniel ^a   Rivero Santana, Amado ^b,c   Perestelo Pérez, Lilisbeth ^c,d,e   Westman, Eric ^a   Wahlund, Lars Olof ^a   Sarría, Antonio ^c,f   Serrano Aguilar, Pedro ^c,d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Canary Foundation of Investigation and Health (FUNCIS)   (Spain)

^c Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas REDISSEC   (Spain)

^d Evaluation Unit of the Canary Islands Health Service (SESCS)   (Spain)

^e UNIVERSIDAD DE LA LAGUNA   (Spain)

^f Instituto de Salud Carlos III Carlos III Institute for Health   (Spain)

Author keywords

Alzheimer's disease; Confounding factors; CSF biomarkers; Meta analysis; Mild cognitive impairment; Systematic review

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; DISEASE MARKER; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; REVIEW; SYSTEMATIC REVIEW;

EID: 84909584181     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00287     Document Type: Review

References (63)

1. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279. doi: 10.1016/j.jalz.2011.03.008
2. Anoop, A., Singh, P. K., Jacob, R. S., and Maji, S. K. (2010). CSF biomarkers for Alzheimer's disease diagnosis. Int. J. Alzheimers Dis. 2010, 606802. doi:10.4061/2010/606802
3. Artero, S., Petersen, R. C., Touchon, J., and Ritchie, K. (2006). Revised criteria for mild cognitive impairment: validation within a longitudinal population study. Dement. Geriatr. Cogn. Disord. 22, 465-470. doi:10.1159/000096287
4. Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837-1844. doi:10.1212/01.wnl.0000219668.47116.e6
5. Bloudek, L. M., Spackman, D. E., Blankenburg, M., and Sullivan, S. D. (2011). Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. JAD 26, 627-645. doi:10.3233/JAD-2011-110458
6. Bouwman, F. H., Schoonenboom, N. S., Verwey, N. A., van Elk, E. J., Kok, A., Blankenstein, M. A., et al. (2009). CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol. Aging 30, 1895-1901. doi:10.1016/j.neurobiolaging.2008.02.007
7. Bouwman, F. H., Schoonenboom, S. N., van der Flier, W. M., van Elk, E. J., Kok, A., Barkhof, F., et al. (2007). CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging 28, 1070-1074. doi:10.1016/j.neurobiolaging.2006.05.006
8. Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., et al. (2009). Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 30, 682-690. doi:10.1016/j.neurobiolaging.2007.08.010
9. Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O. (2012). Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69, 98-106. doi:10.1001/archgenpsychiatry.2011.155
10. Choo, I. H., Ni, R., Schöll, M., Wall, A., Almkvist, O., and Nordberg, A. (2013). Combination of (18)F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. JAD 33, 929-939. doi:10.3233/JAD-2012-121489
11. Deeks, J., Altman, D., and Bradburn, M. (2001). "Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis," in Systematic Reviews in Health Care: Meta-analysis in Context, 2nd Edn, eds M. Egger, G. Davey Smith, and D. G. Altman(London: BMJ Publ. Gr), 285-312.
12. DerSimonian, R., and Laird, N. (1986). Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188. doi:10.1016/0197-2456(86)90046-2
13. Diniz, B. S. O., Pinto Júnior, J. A., and Forlenza, O. V. (2008). Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J. Biol. Psychiatry 9, 172-182. doi:10.1080/15622970701535502
14. Eckerström, C., Andreasson, U., Olsson, E., Rolstad, S., Blennow, K., Zetterberg, H., et al. (2010). Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 29, 294-300. doi:10.1159/000289814
15. Ewers, M., Buerger, K., Teipel, S. J., Scheltens, P., Schröder, J., Zinkowski, R. P., et al. (2007). Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69, 2205-2212. doi:10.1212/01.wnl.0000286944.22262.ff
16. Ewers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M., Petersen, R. C., Jack, C. R. Jr., et al. (2012). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol. Aging 33, 1203-1214. doi:10.1016/j.neurobiolaging.2010.10.019
17. Fagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., et al. (2011). Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch. Neurol. 68, 1137-1144. doi:10.1001/archneurol.2011.105
18. Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L.-O., Sarría, A., and Serrano-Aguilar, P. (2014). Meta-review of CSF core biomarkers in Alzheimer's disease: the state-of-the-art after the new revised diagnostic criteria. Front. Aging Neurosci. 6:1-24. doi:10.3389/fnagi.2014.00047
19. Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio-Chiavetto, L., Bonetti, M., Bonvicini, C., et al. (2013). Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J. Neurol. 260, 640-650. doi:10.1007/s00415-012-6694-0
20. Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., and Sauer, H. (2013). Brain AGE in mild cognitive impaired patients: predicting the conversion to Alzheimer's disease. PLoS ONE 8:e67346. doi:10.1371/journal.pone.0067346
21. Green, M. S., Kaye, J. A., and Ball, M. J. (2000). The Oregon Brain Aging Study: Neuropathology accompanying healthy aging in the oldest old. Neurology 54, 105-113. doi:10.1212/WNL.54.1.105
22. 1-42and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 9, 705-710. doi:10.1038/sj.mp.4001473
23. Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., et al. (2007). Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316-320. doi:10.1159/000100926
24. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., and Minthon, L. (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234. doi:10.1016/S1474-4422(06)70355-6
25. Hardy, R., and Thompson, S. (1998). Detecting and describing heterogeneity in meta-analysis. Stat. Med. 17, 841-856. doi:10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
26. Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., and Hansson, O. (2010). Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. JAD 21, 1119-1128. doi:10.3233/JAD-2010-100207
27. Herukka, S.-K., Hallikainen, M., Soininen, H., and Pirttilä, T. C. S. F. (2005). AB42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297. doi:10.1212/01.WNL.0000156914.16988.56
28. Holtzman, D. M. (2011). CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol. Aging 32, S4-S9. doi:10.1016/j.neurobiolaging.2011.09.003
29. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H.C., Riemen-Schneider, M., De Deyn, P. P., et al. (1999). Improved discrimination of AD patients using beta-amyloid(1-42) and Tau levels in CSF. Neurology 52, 1555-1562. doi:10.1212/WNL.52.8.1555
30. Jong, D., Jansen, W. M. M., Kremer, B. P. H., and Verbeek, M. M. (2006). Cerebrospinal fluid amyloid beta42/phosphorylated Tau ratio discriminates between Alzheimer's disease and vascular dementia. J. Gerontol. 61, 755-758. doi:10.1093/gerona/61.7.755
31. Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151, 65-94. doi:10.7326/0003-4819-151-4-200908180-00136
32. Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., et al. (2003). Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide 42. Arch. Neurol. 60, 1202-1206. doi:10.1001/archneur.60.9.1202
33. Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., et al. (2011). The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7, 386-395. doi:10.1016/j.jalz.2011.05.2243
34. Mattsson, N., Rosén, E., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2012). Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476. doi:10.1212/WNL.0b013e3182477eed
35. Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393. doi:10.1001/jama.2009.1064
36. Mendez, M., Mastri, A., Sung, J., and Frey, W. (1992). Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. Alzheimer Dis. Assoc. Disord. 6, 35-43. doi:10.1097/00002093-199205000-00004
37. Mitchell, A. J. C. S. F. (2009). Phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease - a meta-analysis of 51 studies. J Neurol. Neurosurg. Psychiatr. 80, 966-975. doi:10.1136/jnnp.2008.167791
38. Moher, D., Liberati, A., Tetzlaff, J., Altman, D., and the PRISMA Group. (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8, 336-341. doi:10.1016/j.ijsu.2010.02.007
39. Monge-Argilés, J. A., Muñoz-Ruiz, C., Pampliega-Pérez, A., Gómez-López, M. J., Sánchez-Payá, J., Rodríguez Borja, E., et al. (2011). Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment. Neurochem. Res. 36, 986-993. doi:10.1007/s11064-011-0438-x
40. Monge-Argilés, J. A., Sánchez-Payá, J., Muñoz-Ruiz, C., Pampliega-Pérez, A., Montoya-Gutiérrez, J., and Leiva-Santana, C. (2010). Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease. Rev. Neurol. 50, 193-200.
41. Parnetti, L., Chiasserini, D., Eusebi, P., Giannandrea, D., Bellomo, G., De Carlo, C., et al. (2012). Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. JAD 29, 229-238. doi:10.3233/JAD-2011-111349
42. Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., and Reboldi, P. (2006). Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech. Ageing Dev. 127, 129-132. doi:10.1016/j.mad.2005.09.022
43. Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194. doi:10.1111/j.1365-2796.2004.01388.x
44. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308. doi:10.1001/archneur.56.3.303
45. Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., et al. (2001). Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985-1992. doi:10.1001/archneur.58.12.1985
46. Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., et al. (2013). Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80, 1048-1056. doi:10.1212/WNL.0b013e3182872830
47. Qizilbash, N. (ed.) (2002). Evidenced-based Dementia Practice. Oxford: Blackwell Publishing.
48. Ritchie, K., Artero, S., and Touchon, J. (2001). Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56, 37-42. doi:10.1212/WNL.56.1.37
49. Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., et al. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784-1791. doi:10.1212/WNL.0b013e3182918ca6
50. Shaffer, J. L., Petrella, J. R., Sheldon, F. C., Choudhury, K. R., Calhoun, V. D., Coleman, R. E., et al. (2013). Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 266, 583-591. doi:10.1148/radiol.12120010
51. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413. doi:10.1002/ana.21610
52. Sjögren, M., Vanderstichele, H., Agren, H., Zachrisson, O., Edsbagge, M., Wikkelso, C., et al. (2001). Tau and Ab42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 47, 1776-1781.
53. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the national Institute on Aging working Group. (1998). Consensus report of the working group on: "molecular and biochemical markers of Alzheimer's disease. Neurobiol. Aging 19, 109-116.
54. Toledo, J. B., Korff, A., Shaw, L. M., Trojanowski, J. Q., and Zhang, J. C. S. F. (2013). α-Synuclein improves diagnostic and prognostic performance of CSF tau and AΒ in Alzheimer's disease. Acta Neuropathol. 126, 683-697. doi:10.1007/s00401-013-1148-z
55. van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A., van der Flier, W. M., et al. (2011). Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49, 353-366. doi:10.1515/CCLM.2011.086
56. Victoroff, J., Mack, W., Lyness, S., and Chui, H. (1995). Multicenter Clinicopathological Correlation in Dementia. Am. J. Psychiatry 152, 1476-1484.
57. Vos, S., van Rossum, I., Burns, L., Knol, D., Scheltens, P., Soininen, H., et al. (2012). Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol. Aging 33, 2272-2281. doi:10.1016/j.neurobiolaging.2011.12.017
58. Vos, S. J., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., et al. (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80, 1124-1132. doi:10.1212/WNL.0b013e318288690c
59. Westman, E., Muehlboeck, J.-S., and Simmons, A. (2012). Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage 62, 229-238. doi:10.1016/j.neuroimage.2012.04.056
60. Whiting, P., Rutjes, A., Westwood, M., Mallett, S., Deeks, J. J., Reitsma, J. B., et al. (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529-536. doi:10.7326/0003-4819-155-8-201110180-00009
61. Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., et al. (2004). Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256, 240-246. doi:10.1111/j.1365-2796.2004.01380.x
62. Zamora, J., Abraira, V., Muriel, A., Khan, K., and Coomarasamy, A. (2006). Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med. Res. Methodol. 6:31. doi:10.1186/1471-2288-6-31
63. Zetterberg, H., Wahlund, L. O., and Blennow, K. (2003). Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352, 67-69. doi:10.1016/j.neulet.2003.08.011